Cancer Care in China
First-in-class oncology drugs, the world's first solid-tumor CAR-T, and the largest single-center particle-therapy program on Earth — treatments that, in some cases, exist nowhere else.
If you or someone you love has been told their cancer is too advanced for standard treatment — or that the therapy you need isn't available where you live — China is now offering options that didn't exist a few years ago.
China leads the world in first-in-class oncology drugs: in 2024 alone, 48 brand-new cancer therapies were approved here — more than any other country — including the world's first PD-1×VEGF bispecific antibody (ivonescimab) and the world's first cell therapy for solid tumors (satri-cel). Combined with the only globally accredited proton + carbon-ion center (SPHIC) and one of the world's most active CAR-T ecosystems, China can deliver treatments — at roughly one-third the cost of US care — that simply aren't available elsewhere.
MediPath coordinates the pathway: case review, hospital matching, and end-to-end clinical support.
More first-in-class cancer drugs than any other country.
China approved 48 Class 1 innovative cancer drugs in 2024 — more than any country that year — spanning bispecific antibodies (PD-1×VEGF, PD-1×CTLA-4), antibody-drug conjugates, and the world's first solid-tumor CAR-T. 17 entered priority review and 13 received Breakthrough Therapy designation. For international patients, this means earlier access to therapies that in some cases are not yet approved anywhere else.
48
Class 1 innovative cancer drugs approved in China in 2024 — more than any other country; 13 with Breakthrough Therapy designation
11.1 vs 5.8 mo
median progression-free survival for ivonescimab versus pembrolizumab in advanced NSCLC (HARMONi-2)[R1]
57.1%
objective response rate for satri-cel — the world's first approved solid-tumor CAR-T — in advanced gastric cancer[R4]
Integrated oncology pathways, not just lower prices.
Shanghai Proton & Heavy Ion Center has treated 5,000+ patients with proton + carbon-ion radiation — the world's largest single-center program; the China-originated Beijing Protocol for haploidentical HSCT is now adopted worldwide; 300+ active CAR-T trials run concurrently. For international patients this is access not only to lower cost (often 60–70% below US pricing) but to integrated pathways unavailable elsewhere.
5,000+
patients treated at Shanghai Proton & Heavy Ion Center — the world's largest single-center proton + carbon-ion program[R8]
15.9–42.4%
conversion-to-resectable rates for initially unresectable HCC under China's systematized conversion-therapy framework[R9]
300+
active CAR-T clinical trials running concurrently in China — more than any other country[R10]
Next-generation cancer technology in routine clinical use.
China has become a global center for next-generation cancer technology, deployed in routine clinical practice — not just research: the China-built uEXPLORER total-body PET-CT, China-invented HIFU non-invasive ablation, the domestic HIMM carbon-ion platform, expert-level gastric-cancer AI, and among the world's largest commercial ctDNA liquid-biopsy programs.
194 cm
axial field of view of the China-built uEXPLORER total-body PET-CT — whole-body imaging in a single bed position[R14]
84%
local tumor control in early carbon-ion trials on China's domestically built HIMM platform[R16]
1/3–1/5
of US list price for comprehensive ctDNA liquid-biopsy panels via domestic Chinese platforms[R18]
Signature Institutions for Cancer Care in China
Cancer Hospital, CAMS
中国医学科学院肿瘤医院
Beijing
Comprehensive oncology, surgical oncology, radiation therapy
Peking University Cancer Hospital
北京大学肿瘤医院
Beijing
Solid tumors, gastrointestinal oncology, breast cancer
Fudan University Shanghai Cancer Center
复旦大学附属肿瘤医院
Shanghai
Oncology pathology, comprehensive cancer care, precision medicine
Shanghai Proton & Heavy Ion Center
上海市质子重离子医院
Shanghai
Proton and carbon-ion particle therapy, skull-base tumors, head & neck cancers
Ruijin Hospital
上海交通大学医学院附属瑞金医院
Shanghai
Hematology, leukemia, CAR-T cell therapy
Sun Yat-sen University Cancer Center
中山大学肿瘤防治中心
Guangzhou
Nasopharyngeal carcinoma, hepatocellular carcinoma, comprehensive oncology
Request a Cancer Case Review
Share your diagnosis, pathology and imaging reports, prior treatment history, biomarker or genomic testing, and current goals. Our team can help identify whether China offers a relevant second opinion, a first-in-class drug, cell therapy, particle-therapy, surgical, or interventional pathway — or faster, lower-cost access to a therapy for your condition.